Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinbang mesenchymal stem cell injection
- Development stage
- Phase 1
- Lead developer
- Shandong Xingrui Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Xinbang Mesenchymal Stem Cell Injection is an investigational cell therapy developed by Shandong Xingrui Biotechnology for the treatment of knee osteoarthritis. The product consists of mesenchymal stem cells (MSCs), which are multipotent cells known for their ability to differentiate into various musculoskeletal tissues and their potent immunomodulatory effects. When administered via intra-articular injection, these cells are intended to reduce local inflammation and promote the repair of damaged articular cartilage by secreting a variety of paracrine factors, including cytokines and growth factors. The therapy is currently being evaluated in Phase I/IIa clinical trials in China to assess its safety, tolerability, and preliminary efficacy compared to conventional treatments like sodium hyaluronate.
- Brand names
- Xinbang
- Other names
- Xinbang Mesenchymal Stem Cell InjectionMesenchymal Stem Cell Injection (Shandong Xingrui)
Beyond the preview
Go deeper on Xinbang mesenchymal stem cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xinbang mesenchymal stem cell injection.